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Abstract 
Onconephrology is a rapidly evolving subspecialty that covers all areas of 
renal involvement in cancer patients. The complexity of the field may benefit of a 
well-defined multidisciplinary management administered by a dedicated team. Since 
there is an increasing need to address the needs of this population in dedicated 
outpatient clinics, it is critical to highlight basic characteristics and to suggest areas 
of development. In this brief perspective article we analyze the requirements of an 
Onconephrology clinic in terms of logistic, critical mass of patients, and building of a 
multidisciplinary team. We will further discuss about which patients to refer and 
which conditions to treat. The last part of the paper is dedicated to education and 
performance indicators and to analyze the potential advantages of applying the hub 
and spoke model to this field. The ultimate aim of this experience-based manuscript 
is to initiate to debate about how an Onconephrology outpatient clinic might look 
like in order to ensure the highest quality of care to this growing population of 
patients. 
 
KEY WORDS: onconephrology; cancer; kidney; outpatient clinic; multidisciplinary 
team. 
 
RUNNING TITLE: onconephrology outpatient clinic. 
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Introduction: the cancer-kidney connection 
Onconephrology is a rapidly evolving subspecialty area that focuses on all 
aspects of kidney disease in cancer patients. Recently, we proposed a “decalogue of 
onconephrology” to highlight several of the areas where nephrologists and 
oncologists should collaborate to provide cutting-edge care for patients afflicted 
with cancer and kidney diseases
1
. In that paper, we highlighted the following 10 
points of contact between the two specialties 1) acute kidney injury (AKI) and 
chronic kidney disease (CKD) in cancer patients; 2) nephrotoxic effects of anticancer 
therapy; 3) paraneoplastic renal manifestations; 4) management of patients 
nephrectomized for a kidney cancer; 5) renal replacement therapy and oncological 
treatments; 6) kidney transplantation in cancer survivors and cancer risk in ESRD 
patients; 7) oncological treatment in kidney transplant patients; 8) pain management 
in cancer patients with concomitant kidney diseases, 9) development of guidelines 
specific for onco-nephrology patients and 10) design of clinical trialswith onco-
nephrology endpoints
1
. 
Well-defined multidisciplinary management of cancer patients with kidney 
disease can help ensure the highest quality of care that is administered by a 
dedicated specialty team with experience in these complex issues. 
To aid implementation of this model, it is critical to identify 
recommendations and minimal requirements for the development of 
onconephrology outpatient clinics. There are examples of these types of 
multidisciplinary clinics in other fields of oncology where various specialists are 
brought together to improve outcomes and care pathways
2, 3
.  The objective of our 
experience-based paper is to initiate a dialogue on what such a clinic might look like 
to successfully serve this growing population of patients. 
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Onconephrology clinics – Basic requirements 
To develop and sustain a successful outpatient clinic for patients suffering from 
cancer and kidney disease, a number of basic requirements must be met. In our 
opinion, the following requirements are needed to create a successful and efficient 
onconephrology outpatient clinic.  
 
1) Critical mass of patients 
For many reasons, there should be a sufficient number of patients enrolled in 
the clinic.  This is to ensure operational efficiency, financial viability and to develop 
expertise in the unique overlap of kidney problems seen in patients with cancer.  
Recent studies demonstrated that the prevalence of estimated glomerular filtration 
rate (eGFR) below 60 ml/min in patients affected by solid tumors overall exceed 
12%
4
 and a 1 year risk of AKI of any stage may be as high as 17% for incident cancer 
patients
5
. Since the cancer incidence in Europe and USA approaches 300 cases per 
100,000 inhabitants/year
6
, the clinic should be affiliated with a large or medium-size 
hospital (serving at least 500,000 inhabitants). At least 150 new patients per year 
would be thus considered a sufficient size to maintain a robust clinic. In certain 
major cancer centers it is ideal that the onconephrology clinic is physically housed in 
the cancer hospital. The choice of 150 new patients, as a minimum number of cases 
justifying the development of an Onco-Nephrology clinic, is empiric, though justified 
on the basis of the experience of three of the co-Authors of this paper, who have 
already created such clinics across Europe; of course, this should be considered just 
as a starting number, which is expected to increase over time. 
In most academic centers, creating this critical mass will be needed to 
enhance the experience and expertise of the onconephrologist. 
 
2) Proximity to the Hematology and Oncology ward 
In addition to an adequate patient number, the clinic should be located 
within a reasonable distance from the primary site of oncology care. This is 
particularly important when a patient develops significant AKI or progressive CKD 
that might impede active cancer therapy. Rapid nephrology evaluation and 
treatment would be greatly facilitated by a nearby onconephrology clinic. 
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Furthermore, an active, local and bidirectional relationship between nephrologists 
and oncologists would promote shared decision-making and development of 
collaborative care models. This would engender a comprehensive evaluation of 
patients that would hopefully result in improved outcomes
7
.  For example, the 
onconephrology team could provide critical information about life expectancy and 
quality of life for patients facing decisions regarding dialysis initiation. This 
integrative, patient-centered, medical approach is key to ensure appropriate and 
optimized care of the patient and their diseases, including cancer and comorbidities. 
An ideal model is to allow the onconephrologist to see the cancer patient in 
the hematology/oncology office. This might be logistically possible in some centers 
and not others. Thus, a reasonable physical proximity would be a key requirement to 
provide a structured and multidisciplinary environment for effective management of 
patients referred to the clinic. 
Of course, not every given patient has to be physically seen by the 
multidisciplinary group; furthermore, a tele-medicine approach could be very useful 
within the hub and spoke model described later within this manuscript. 
 
3) Availability of Medical Records across Clinics 
The history of patients with cancer is complicated with multiple visits to 
various specialists and complex medical regimens that can change rapidly depending 
upon side effects and tumor response. This is particularly true for patients with 
extended therapeutic courses. These patients have often undergone a large number 
of diagnostic studies and treatment regimens. The availability of original source 
documents (which, once again, is facilitated by proximity) would thus be key to 
having a complete understanding of the patient’s past and present medical (and 
oncologic) history. The easy availability of this information would facilitate a rapid, 
comprehensive evaluation by the consulting nephrologist. 
 
4) Shared (electronic) database 
Since the subspecialty of onconephrology is still in its infancy, both cancer 
specialists and nephrologists may benefit immensely from knowledge of previous 
cases, their treatments and outcomes. A comprehensive data-base containing 
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electronic medical records (EMRs) would represent a source of precious information 
(both prospective and retrospective) for clinical and research purposes. Such 
databases can be “mined” to look for outcomes of specific subgroups of patients and 
can be used to develop hypotheses for future studies. 
 
5) Referral to the Onconephrologist 
Although an onconephrology outpatient clinic may operate once or twice a 
week (or more frequently as needed), a dedicated onconephrologist should always 
be available to provide expertise.  
Since a sizeable number of patients falling within the competence of an 
onconephrological evaluation are often hospitalized, an onco-nephrology 
consultation should be available, on demand, also for inpatients; specific protocols 
should thus be implemented within the hospital in order to clearly define when this 
kind of consultation is needed within the inpatient ward (e.g. in the case of those 
conditions reported in table I), and how to ask for it. 
The onco-nephrology consultant must be versed and knowledgeable of the 
complex relationships between cancer and the kidney, the pharmacological 
properties of all antineoplastic drugs, and the harm to benefit ratio of antineoplastic 
treatment strategies in patients with underlying kidney disease.  
Considering the need of evaluating some of these patients on a short notice, 
as well as obvious organization issues such as vacations, illnesses, etc …, more than 
one dedicated specialist is needed in order to fulfill all the above requirements. 
Overall, a curriculum in onconephrology, such as the one developed by the 
American Society of Nephrology
8
, would be useful to facilitate competency in this 
complicated area. 
 
6) Multidisciplinary Team 
A multidisciplinary approach is critical for the success of this model
9
. 
Multidisciplinary care requires a pro-active and bidirectional relationship between 
the various specialists (see core team below) involved in the patient’s care. 
Furthermore, performance indicators and regular assessment of outcomes are 
essential to monitor the effectiveness of the outpatient clinic and to allow changes 
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and improvements over time. It is important to recognize that multidisciplinary care 
does not mandate the participation of onconephrologists on all tumor boards. We do 
believe that a significant number of those patients brought for multidisciplinary 
discussion into the GU tumor board could benefit from the presence of a 
nephrologist. If addition, the onconephrologist’s opinion can be sought when 
needed for complex cases where kidney disease is integral to the diagnostic or 
therapeutic plans. Where clear renal issues exist or may develop, protocols for early 
nephrology involvement are important. In complex drug toxicities such as immune 
check-point inhibitor induced acute nephritis
10
 or venetoclax induced tumor lysis 
syndrome
11
, an onconephrologist’s expertise can help standardize care in the 
inpatient and outpatient settings.  
 
7) Core team 
A core team of various specialists dealing with cancer patients with kidney 
disease and issues is mandatory. The core team would consist of nephrologists, 
hematologists and oncologists along with a dedicated data manager, nursing and 
care coordinator team members. The team members should ideally have a 
specialized training in onconephrology and, should spend an agreed amount of 
weekly time with these patients to maintain proficiency
8
. Participating nephrologists 
should also partake of continuing professional medical education. All core team 
members must attend multidisciplinary meetings for case management and audit 
purposes. Other specialists including urologists, radiation therapists, pathologists, 
radiologists, palliative care-providers, and others would be invited to attend 
multidisciplinary rounds, as needed.  This model currently exists in many U.S. Cancer 
Centers and emerges in many European countries. Notably, within the Onco-
Nephrological web community of the American Society of Nephrology, this is a topic 
that has been recently the object of a dedicated forum (http://community.asn-
online.org/communities/community-home?communitykey=0ca61c6c-1f2f-4f15-
9ae5-86fc6ef4c260&tab=groupdetails, accessed on May 8, 2018). 
In addition, case discussions, which should be held at least weekly, must be attended 
by all involved professionals.  
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Furthermore, the role of a dedicated Pharmacologist, within or not the core 
team, is in our opinion critical in order to provide advice on possible pharmacologic 
interactions (in a population of patients highly comorbid and thus taking many 
different drugs), and to explore pharmacokinetic properties of each given 
oncological drugs in CKD patients, as well as in those on dialysis. 
 
8) Involvement of other health Professionals 
Depending on different organization systems, which can greatly vary from 
country to country, different health professionals, including physician extenders, 
nurses, and post-graduate students, could be involved in the activities of the clinic, 
expecially when patients need to be seen on a short notice or for frequent follow-up 
controls. 
 
9) Availability of certain diagnostic tests 
Ideally, a histological evaluation of both non-neoplastic and neoplastic tissue within 
the pathologic specimens of resected kidney cancer patients would be mandatory, as 
claimed by the 2012 International Society of Urologic Pathology (ISUP) consensus 
conference
12
. This evaluation would indeed provide important details for the future 
management of these patients. However, since the implementation of this 
evaluation could be troublesome on a wide scale, we believe that optical microscopy 
analysis of the normal tissue should be reported in almost all patients’ pathological 
reports, while immunofluorescence and/or electron microscopy should be 
performed in more specialized centers (i.e. the hubs, as reported below) whenever 
needed, and tissue preserved for possible future analyses. 
Following the 2012 International Society of Urologic Pathology (ISUP) consensus 
conference
12
, has become mandatory; indeed, the study of the non-neoplastic tissue 
could provide informations of the utmost utility for a comprehensive nephro-
oncological evaluation.  
Furthermore, a comprehensive and efficient workup for a patient attending the 
Onco-Nephrology clinic often requires the prompt execution of few diagnostic tests. 
Those providing important informations for many patients include renal ultrasound 
(including Doppler interrogation), venous blood gas (VBG) analysis, and ambulatory 
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blood pressure monitoring (ABPM), though the importance of the availability of the 
latter two has not been agreed upon by all co-Authors. Indeed, although 
hypertension is, by far, the most common treatment-related renal adverse event 
observed in cancer patients on antiangiogenic treatment, it is clear that ABPM is not 
strictly necessary in many other cancer patients. As far as VBG, although it provides 
in timely manner important informations, able to immediately drive therapeutic 
interventions, such as pH, bicarbonates, ionized calcium, and potassium levels, these 
informations can be also provided without the need of a blood gas and in a timely 
manner by a stat lab. Thus, since in some Countries (e.g. the US) institution-specific 
regulations don’t allow the presence of lab equipment in outpatient clinical space, 
stat labs should be regarded as a realistic substitute for VBG. 
These tests, in particular renal ultrasound, maintain the potential to provide critical 
information about the cause of AKI or CKD in the cancer patient, monitor for acid-
base disturbances, a blood pressure changes due to anti-cancer drugs (both 
hypotension and hypertension). The ability to promptly perform these tests would 
allow rapid, efficient care in the spirit of the state-of-the-art Onco-Nephrology clinic 
care plan. 
 
Which patients are appropriate for the Onco-Nephrology clinic? 
In some countries, chemotherapy is only validated after regular multidisciplinary 
meetings. At that stage, it might be interesting to obtain a minimal renal check-up 
before any treatment to identify “at risk patients” and further educate oncologists 
and patients about a number of classical kidney failure risks. 
In previous publications, we and others have identified the main areas of interest 
and intervention of Onco-Nephrology
1,13-15
. In our opinion, there are categories of 
cancer patients who must be always referred to the Onco-Nephrology outpatient 
clinic for a comprehensive evaluation. Table 1 notes the types of patients and 
reasons for referral to the outpatient clinic. 
 
Minimal workup for the Onco-Nephrology patient 
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The minimal workup needed by a cancer patient with some form of kidney 
disease is summarized in table 2. In general, the workup should include routine 
generic examinations and tests, as well as tests specific for the kidney or oncological 
aspects of the patient’s care. 
It is critical that patients have an accurate estimate of GFR to ensure problem 
dosing of medications and avoidance of side effects. The best estimating equation 
for GFR to gauge kidney function has not been well studied in patients with cancer 
and kidney disease. These tests have their strengths and limitations in the general 
population and likely have other issues in the patients being evaluated in the 
onconephrology clinic
16-19
. Although some authors have suggested that MDRD could 
underestimate kidney function in cancer patients
20,21
, the MDRD and CKD-EPI 
equations are still the two equation recommended also in this setting
22-24
. It is likely 
that they will provide similar estimates of kidney function in patients with stable CKD 
and they are not appropriate to use in patients with AKI where patient’s GFR is not in 
the steady state
25
. A recent publication evaluating GFR estimating equations in 
cancer patients noted that BSA-adjusted CKD-EPI method appears to be the most 
accurate published model to estimate GFR in patients with cancer. BSA-adjusted 
CKD-EPI, based on the analysis of data from 2,582 cancer patients using 51Cr-EDTA 
GFR measurement as the gold standard, was found to be the most accurate and least 
biased published model to estimate GFR
17
. The authors also developed a new model 
that further improves the estimation of GFR and allo s calculation of predictive 
confidence intervals for this estimation. The new model has been implemented as an 
online tool found at the following link: 
http://tavarelab.cruk.cam.ac.uk/JanowitzWilliamsGFR/. This new model to estimate 
GFR may represent a new standard of care and should be further examined along 
with BSA-adjusted CKD-EPI in clinical onconephrology practice. 
 
Diseases managed in the Onconephrology outpatient clinic 
Based on our experience, the areas where a joint onconephrology approach 
(consultation) is mandatory are those reported in table 3
14
. The involvement of 
specialists other than nephrologists and oncologists should be considered in many of 
the case discussions, diagnostic approaches, and treatment plans.  
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Development of protocols for the Onconephrology clinic  
The development of specific protocols for the screening, management, and 
follow-up of cancer patients with various kidney problems would be one of the 
major goals of onconephrology clinic.  Different protocols should be proposed and 
discussed within the core team, brought to the attention of multidisciplinary teams 
(MDTs), and then disseminated to all onconephrology clinics (table 4).  These 
protocols should be shared across centers in order to support development of best 
practices. 
In addition to developing various clinical protocols, it should be part of the 
onconephrology core team’s mission to participate in the proposal, design, and 
conduction of clinical trials addressing specific issues related to cancer and kidney 
disease. Finally, lobbying to introduce well-defined and clinically relevant nephrology 
endpoints into oncological clinical trials (from phase I to post-marketing phase IV 
studies) would be of the utmost importance
26
 
 
Audits and (proposed) indicators of performance 
The onconephrology clinic must hold regular internal audit meetings in order to 
review indicators of performance, establish or change procedures, and amend 
protocols as necessary
2,27
. Written protocols should be developed and agreed upon 
by the multidisciplinary members, and then discussed and re-evaluated at any audit. 
Revising many of the proposed indicators of performance over time, in order to 
dismiss those not relevant, and implement novel ones (e.g. those emerging from the 
use of novel anticancer agents/strategies), will be an integral part of the 
indicators/audits system we propose. 
Ideally, among possible initial indicators of performance, we propose those 
described in table 5. 
 
The “hub and spoke” model for onconephrology 
While one of the requirements for an onconephrology outpatient clinic is the 
presence of a critical mass of patients, the need for an onconephrology consultation 
can also occur in a small, peripheral hospital. We believe that the concept of the hub 
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and spoke model
28,29
 could optimally be applied to onconephrology. Indeed, the goal 
of the hub and spoke model is to position a specialized care delivery facility as a 
central hub, and build a network of feeders or spoke facilities. This system creates 
value by generating learning curve benefits at the hub, as well as by operating all 
assets within the network at maximum utilization. Since one of the goals of this 
model is to bring complex cases to the central hub, where they could be managed at 
the highest level of competence, this could be achieved either at the central hub or 
virtually. Web based consultations, or even MDT rounds could potentially replace 
physical visits in the case of logistical issues, bringing the competence of the hub 
directly to the spoke.  
   
Education and training to create the Onco-Nephrologist 
In the introduction to the ASN core curriculum in onconephrology
8
, Perazella 
and Rosner clearly stated that one of the goals of such a tool was to “… provide the 
ASN membership, including veteran nephrologists, newly minted nephro-clinicians, 
and fellowship trainees, with the building blocks on which further information can be 
added as technology advances”. This would be a potential model to follow on an 
international level around the world. Nephrologists must be prepared to care for 
patients with cancer and renal complications. Indeed, as already evidenced, the 
renal manifestations of cancer have many unique features, and these conditions 
often require specialized approaches to manage all of them. Furthermore, the 
rapidly evolving field of cancer treatments requires a comprehensive approach from 
the different and varied expertise of nephrologists, oncologists, and many other 
specialists. As such, it is essential for all who are interested in onconephrology to 
develop expertise in the practice of this intriguing and complex subspecialty. Specific 
courses in post-graduate training in Nephrology and Oncology could be employed to 
increase the awareness of onconephrology issues, and to prepare the next 
generation of specialists in this subspecialty. 
 
Foreseen obstacles in the development of an onconephrology outpatient clinic 
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The development and implementation of every novel activity is almost 
always coupled with difficulties, obstacles, and barriers; this is for sure also the case 
of our proposal. 
Recognizing these pitfalls is the first step to overcome them. According to our 
experience, we have summarized these foreseen obstacles in Table 6, coupling each 
requirement we have highlighted with relative obstacles.  Notably enough, in our 
opinion, the first and most important obstacle to overcome is the typical  nihilistic 
approach surrounding patients with both kidney diseases and cancer.
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Conclusions 
Due to the dramatic improvements in cancer treatment, a growing number of 
patients affected by cancer now survive longer, often with a adequate quality of life. 
However, the presence of concomitant chronic illnesses, including kidney disease, 
may greatly complicate their care and alter their quality and quantity of life. The 
relationship between kidney disease and cancer could be regarded as ‘circular’
30
. For 
example, the presence of a tumor or its treatment may directly or indirectly damage 
renal function and the presence of kidney disease in cancer patients may worsen 
prognosis, increase mortality, and disturb the bioavailability and/or safety profile of 
antineoplastic drugs in patients with underlying kidney disease. 
Onconephrology is presently more experience-, than evidence-based. Indeed, 
onconephrology has developed in recent years with the main intent of managing 
those orphan patients (e.g. those with CKD, ESRD, on dialysis, transplanted, etc …) 
who are not enrolled into clinical trials (the cornerstones of evidence-based 
medicine), who cannot benefit from the availability of guidelines (which indeed do 
not exist), or even of sound supporting literature (mainly limited to single case 
reports or small retrospective series). Only a thorough knowledge of the issues of 
onconephrology and of the drugs and their pharmacokinetic properties in patients 
with cancer and kidney diseases, together with a tight inter-specialty collaboration, 
can provide these patients a better treatment and management. 
Thus, a multidisciplinary onconephrology team, led by cancer specialists and 
nephrologists, but also including other health professionals, is critical to providing 
the best possible care for this group of cancer patients. Here we have proposed 
minimal requirements and recommendations to develop an onconephrology 
outpatient clinic, with the overall aim of providing experience-based considerations 
that will initiate further discussion on this important and growing specialty area. 
Finally, as far as multidisciplinarity, we cannot but agree with the following strong 
statement by Champiat et al.: “Organ specialist … referral is needed for mainly two 
reasons: for oncologists to learn proper management of specific … toxicities, but also 
for organ specialists to increase their knowledge about these new drug-mediated 
toxicities and therefore creating a virtuous circle for patients management”
31
. 
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Table 1. Patients for whom referral to the onconephrology Clinic is suggested 
 
Type of patient(s) Main issue(s) 
Cancer patients with kidney impairment 
before, during and after active cancer 
treatment 
- To guarantee the best cancer treatment 
possible, without unnecessary dose 
reduction and/or treatment interruptions, 
which could hamper the possibility of 
success of the oncological treatment 
Cancer patients at risk of kidney impairment 
- due to concomitant illnesses (e.g. 
hypertension, diabetes, etc. ) 
- due to the potential nephrotoxicity 
of the planned treatment 
- To prevent the development of kidney 
impairment, possibly leading to dose 
reduction or treatment interruption 
- education of oncologists and patients 
about classical kidney failure risks  
Cancer patients developing adverse renal 
events from antineoplastic treatment 
- AKI 
- Worsening of CKD 
- Hypertension 
- Proteinuria 
- Electrolyte disturbances 
- TMA 
Cancer patients at significant risk of Contrast-
Induced-Nephropathy 
- Prevention of AKI or of worsening of CKD 
through implementation of prophylactic 
measures 
Kidney cancer patients at risk for post-surgical 
(or post-ablative) AKI or progressive CKD 
- Prevention of AKI or of worsening of CKD 
- Management of treatment-related AEs 
Patients with urothelial cancer (all) - Prevention of AKI or of worsening of CKD 
- Prevention/management of obstructions 
- Prevention/management of chronic 
infections 
- Management of treatment-related AEs 
Patients with suspected or de facto 
paraneoplastic glomerulopathies 
- Screening for an occult cancer (if any) 
- Diagnosis 
- Management strategies (e.g. use of 
immune-suppressive agents in the cancer 
patient) 
Transplantation patients 
- donors 
- recipients 
- transplanted patient who develops  
cancer 
- When to allow transplantation or 
donation in a patient with previous or an 
active cancer 
- Management strategies (e.g. use of 
immune-suppressive agents in the cancer 
patient) 
Cancer patients on dialysis - Management of drug dosing, toxicity 
- Use of erythropoietin stimulating agents 
- Shared decision making  
Hematological cancer patients - Management of renal involvement in 
myeloma and lymphomas 
- Management of secondary amyloidosis 
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Bone metastases in cancer patients with CKD - Management of bone-targeted therapies 
(bisphosphonates or denosumab) 
- Management of bone-targeted therapies-
induced hypocalcemia 
AKI, acute kidney injury; CKD, chronic kidney disease; TMA, thrombotic microangiopathy; CIN, 
contrast induced nephropathy; AEs, adverse events 
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Table 2. Clinical evaluation of the patient with cancer and kidney disease 
 
• Physical examination 
• Evaluation of co-morbidities and pre-existing kidney impairment (clinical and subclinical) 
• Evaluation of ongoing (and previous) therapies, both oncological and not oncological 
• Renal function tests  
- Estimated glomerular filtration rate (eGFR) with a CKD-EPI formula 
- When needed, directly measure eGFR (creatinine clearance, nuclear medicine 
GFR evaluation, etc …) 
• Basic hematology, including differential white blood cell count 
• Urinalysis and examination of urinary sediment examination; quantification of proteinuria 
• Electrolytes and serum enzymes (including serum calcium, phosphorus, uric acid and 
magnesium, LDH and uric acid). 
Obtain trends of all pertinent labs including SCr, LDH, CBC and urine protein/creatinine 
ratio  
• Acid-base balance and abnormalities 
• Blood pressure (including ABPM whenever necessary) 
• Basic imaging: renal/abdominal US 
• Basic imaging: oncological disease status evaluation, as appropriate (CT, MRI, etc …) 
CKD-EPI, chronic kidney disease epidemiology; CBC, complete blood count; SCr, serum creatinine; 
LDH, lactate dehydrogenase; ABPM, ambulatory blood pressure monitoring; US, ultrasound; CT, 
computed tomography; MRI, magnetic resonance imaging. 
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 Table 3. Disease management in the Onconephrology clinic 
 
• Management of renal AEs from anticancer therapy and dose modification for 
- cytotoxic chemotherapy, 
- targeted agents, 
- immune checkpoint inhibitors and 
- bone targeting agents, 
 in patients with conserved or altered renal function (including ESRD and dialysis patients) 
• Management of renal complications from  
- surgery 
- radiation therapy 
- other diagnostic and therapeutic procedures (e.g. renal stenting, etc.) 
• Management of CIN 
• Management of transplantation patients’ issues 
- management of kidney transplant patient that develops a cancer 
- clearance (or not) of a cancer patient to donate for kidney 
transplantation  
- clearance (or not) of a cancer patient to receive a kidney transplantation 
- administration of targeted therapy and or immunotherapy  in a kidney 
transplant patient. 
• Management of paraneoplastic nephrological syndromes, including screening or not these 
patients 
• Choice of anti-pain therapy and dose adaptation in cancer patients with renal impairment 
• Discussion of ethical issues (to treat or not to treat cancer patients in dialysis or with 
ESRD) 
AEs, adverse events; ESRD, end stage renal disease; CIN, contrast induced nephropathy 
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Table 4. Onco-Nephrology protocols 
 
• Screening and follow-up protocols to prevent kidney damage for each given antineoplastic 
agent 
• Screening and follow-up protocols to prevent kidney damage from radiology contrast-
media 
• Developing indications for kidney biopsy, and implementing its use in cancer patients 
• Screening and follow-up protocols for cancer patients in dialysis and with ESRD 
• Screening and follow-up protocols for transplantation patients (evaluation and possibly 
prevention of the risk of malignancy) 
• Screening and follow-up protocols for transplantation candidates 
  - if and when to transplant a patient who previously had cancer, 
  - if and when allowing the donation from a patient who previously had a cancer 
  
Page 22 of 25Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
23 | P a g e  
 
Table 5. Performance indicators for an Onco-Nephrology clinic 
 
Indicator of performance Reason(s) Value to be achieved 
(on 1
st
 year) 
Percentage of patients 
discussed by the core team 
To ensure that (ideally) all patients 
presenting with Onco-Nephrology issues 
are adequately evaluated at least by the 
core team 
100% 
Percentage of patients 
brought to the attention of 
the MDT 
To ensure that all complex patients 
presenting are brought to the attention of 
and discussed within each given MDT 
100% 
Number of episodes of AKI 
from anticancer treatment 
AKI episodes leads to worsening of cancer 
patients’ prognosis (especially in terms of 
reduced OS); furthermore, increases also 
CKD 
Reduction of at least 
25% as compared to 
the previous year 
Number of episodes of CIN CIN episodes lead to both AKI and 
worsening of CKD 
Reduction of at least 
25% as compared to 
the previous year 
Number of visits to ER ward 
due to kidney toxicity from 
oncological treatments 
Increase of costs and hospitalization rates Reduction of at least 
25% as compared to 
the previous year 
Number of hospital 
admissions due to kidney 
toxicity 
Increase of costs Reduction of at least 
25% as compared to 
the previous year 
Number of treatment 
interruptions due to kidney 
toxicity 
Potentially hampers treatment efficacy Reduction of at least 
25% as compared to 
the previous year 
Number of treatment 
withdrawals due to kidney 
toxicity 
Hampers treatment efficacy preclusing 
the continuation of potentially life-
extending treatments 
Reduction of at least 
20% as compared to 
the previous year 
Number of drug-related 
adverse reactions due to 
kidney disease 
Increase morbidity and (potentially) also 
mortality, as well as hospitalization rates; 
increase also treatment interruptions and 
withdrawals 
Reduction of at least 
25% as compared to 
the previous year 
Patients’ satisfaction Linked to improved QoL 100% 
Healthcare workers’ 
satisfaction 
Linked to improved medical service 
quality and patients’ satisfaction.  
100% 
MDT, multidisciplinary team; CKD, chronic kidney disease; CIN, contrast induced nephropathy, 
QoL, quality of life 
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Table 6. Foreseen obstacles in establishing an outpatient onconephrology clinic 
 
Specific requirement Obstacle(s) 
Critical mass of patients - Presence of a small oncology/hematology 
service 
- Nihilistic approach to patients with both 
kidney diseases and cancer 
Proximity to the hematology/oncology ward Structural difficulties (especially in Hospitals 
not built to favour multidisciplinarity) 
Availability of medical records across clinics Not an issue 
Shared (electronic) data-base Not an issue 
Referral to the Onco-Nephrologist - Clear-cut identification of the Onco-
Nephrology referral specialist within the 
hospital 
- Clear-cut definition of the patients to 
refer for consultation 
- Information/education of physicians who 
should know when an onconephrological 
referral is needed 
Multidisciplinary team and core team - Time 
- Bringing together and motivating 
different specialists towards a real 
multidisciplinary consultation 
- Nihilistic approach to patients with both 
kidney diseases and cancer 
- Need for a specific training and for 
maintaining proficiency in Onco-
Nephrology 
Involvement of other health professionals Bringing together and motivating different 
health professionals and caregivers 
Availability of certain diagnostic tests Not an issue 
Appropriateness of patients - Clear-cut definition of the patients to 
refer for consultation 
- Nihilistic approach to patients with both 
kidney diseases and cancer 
Minimal workup - Sharing minimal requirements among 
different specialists 
- Sharing a common language 
- Clear-cut evaluation of kidney function 
Disease management Nihilistic approach to patients with both 
kidney diseases and cancer 
Development of specific protocols Identification of topics and objectives 
Audits and indicators of performance - Time and personnel 
- Variability of indicators over time 
Hub and spoke model - Costs 
- Bringing together and motivating 
different structures and health 
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professionals 
Education and training - Identification of educational needs 
- Standardization of trainees’ curriculum 
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